These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

147 related items for PubMed ID: 16493198

  • 61. The role of thiopurine metabolite monitoring in inflammatory bowel disease.
    Beswick L, Friedman AB, Sparrow MP.
    Expert Rev Gastroenterol Hepatol; 2014 May; 8(4):383-92. PubMed ID: 24684593
    [Abstract] [Full Text] [Related]

  • 62. On the limitation of 6-tioguaninenucleotide monitoring during tioguanine treatment.
    de Boer NK, de Graaf P, Wilhelm AJ, Mulder CJ, van Bodegraven AA.
    Aliment Pharmacol Ther; 2005 Sep 01; 22(5):447-51. PubMed ID: 16128683
    [Abstract] [Full Text] [Related]

  • 63. Sustained effectiveness, safety and therapeutic drug monitoring of tioguanine in a cohort of 274 IBD patients intolerant for conventional therapies.
    Simsek M, Deben DS, Horjus CS, Bénard MV, Lissenberg-Witte BI, Buiter HJC, van Luin M, Seinen ML, Mulder CJJ, Wong DR, de Boer NKH, van Bodegraven AA.
    Aliment Pharmacol Ther; 2019 Jul 01; 50(1):54-65. PubMed ID: 31094013
    [Abstract] [Full Text] [Related]

  • 64. Ocular hemorrhage secondary to thioguanine-associated veno-occlusive disease in a child with acute lymphoblastic leukemia in delayed intensification.
    Bhunia N, Yeager ND, Colace SI, Buzzaco D, Bajwa RPS.
    Pediatr Transplant; 2020 Feb 01; 24(1):e13638. PubMed ID: 31840375
    [Abstract] [Full Text] [Related]

  • 65. [Nodular regenerative hyperplasia as a complication of thiopurine treatment in a patient with inflammatory bowel disease].
    Cohen-Ezra O, Avni Y, Morgenstern S, Ben-Ari Z.
    Harefuah; 2012 Dec 01; 151(12):675-8, 721. PubMed ID: 23330258
    [Abstract] [Full Text] [Related]

  • 66. How are thiopurines used and monitored by Swedish gastroenterologists when treating patients with inflammatory bowel disease?
    Hindorf U, Andersson P.
    Scand J Gastroenterol; 2011 Oct 01; 46(10):1215-21. PubMed ID: 21793634
    [Abstract] [Full Text] [Related]

  • 67. Portal hypertension develops in a subset of children with standard risk acute lymphoblastic leukemia treated with oral 6-thioguanine during maintenance therapy.
    Broxson EH, Dole M, Wong R, Laya BF, Stork L.
    Pediatr Blood Cancer; 2005 Mar 01; 44(3):226-31. PubMed ID: 15503293
    [Abstract] [Full Text] [Related]

  • 68. [Continued development of drugs: the path of thioguanine].
    Simsek M, de Boer NKH, Mulder CJJ.
    Ned Tijdschr Geneeskd; 2018 Mar 01; 162():D1757. PubMed ID: 29350120
    [Abstract] [Full Text] [Related]

  • 69. 6-TG for IBD. simple, but safe?
    Tremaine WJ.
    Am J Gastroenterol; 2003 May 01; 98(5):950-2. PubMed ID: 12809812
    [No Abstract] [Full Text] [Related]

  • 70. Thiopurine metabolite monitoring in paediatric inflammatory bowel disease.
    Ooi CY, Bohane TD, Lee D, Naidoo D, Day AS.
    Aliment Pharmacol Ther; 2007 Apr 15; 25(8):941-7. PubMed ID: 17402998
    [Abstract] [Full Text] [Related]

  • 71. Drug rediscovery in gastroenterology: from off-label to on-label use of thioguanine in inflammatory bowel disease.
    de Boer NKH, Simsek M, Meijer B, Neurath MF, van Bodegraven A, Mulder CJJ.
    Gut; 2023 Oct 15; 72(10):1985-1991. PubMed ID: 37380330
    [Abstract] [Full Text] [Related]

  • 72. Letter: Thioguanine, an underutilised option in inflammatory bowel disease?
    Chetwood JD, Paramsothy S, Leong RW.
    Aliment Pharmacol Ther; 2024 Apr 15; 59(8):1009-1010. PubMed ID: 38523080
    [No Abstract] [Full Text] [Related]

  • 73. Histopathology of liver biopsies from a thiopurine-naïve inflammatory bowel disease cohort: prevalence of nodular regenerative hyperplasia.
    De Boer NK, Tuynman H, Bloemena E, Westerga J, Van Der Peet DL, Mulder CJ, Cuesta MA, Meuwissen SG, Van Nieuwkerk CM, Van Bodegraven AA.
    Scand J Gastroenterol; 2008 Apr 15; 43(5):604-8. PubMed ID: 18415755
    [Abstract] [Full Text] [Related]

  • 74. The pharmacokinetic effect of discontinuation of mesalazine on mercaptopurine metabolite levels in inflammatory bowel disease patients.
    Gilissen LP, Bierau J, Derijks LJ, Bos LP, Hooymans PM, van Gennip A, Stockbrügger RW, Engels LG.
    Aliment Pharmacol Ther; 2005 Oct 01; 22(7):605-11. PubMed ID: 16181300
    [Abstract] [Full Text] [Related]

  • 75. A well-tolerated and rapidly acting thiopurine for IBD?
    Florin THJ, Wright JD, Jambhrunkar SD, Henman MG, Popat A.
    Drug Discov Today; 2019 Jan 01; 24(1):37-41. PubMed ID: 30196006
    [Abstract] [Full Text] [Related]

  • 76. Efficacy of drugs used in the treatment of IBD and combinations thereof in acute DSS-induced colitis in mice.
    Sann H, Erichsen Jv, Hessmann M, Pahl A, Hoffmeyer A.
    Life Sci; 2013 Apr 09; 92(12):708-18. PubMed ID: 23399699
    [Abstract] [Full Text] [Related]

  • 77. 6-Thioguanine can cause serious liver injury in inflammatory bowel disease patients.
    Walker TR, Leichter AM.
    J Pediatr Gastroenterol Nutr; 2004 Feb 09; 38(2):232-3. PubMed ID: 14974466
    [No Abstract] [Full Text] [Related]

  • 78. Usefulness of thiopurine metabolites in predicting azathioprine resistance in pediatric IBD patients.
    Nguyen TV, Nguyen TM, Lachaux A, Boulieu R.
    J Clin Pharmacol; 2013 Sep 09; 53(9):900-8. PubMed ID: 23856979
    [Abstract] [Full Text] [Related]

  • 79. 6-thioguanine-buried alive?
    Herrlinger KR, Schwab M, Fellermann K, Stange EF.
    Gastroenterology; 2004 Mar 09; 126(3):940-1; author reply 941-2. PubMed ID: 14988863
    [No Abstract] [Full Text] [Related]

  • 80. A novel mouse model of veno-occlusive disease provides strategies to prevent thioguanine-induced hepatic toxicity.
    Oancea I, Png CW, Das I, Lourie R, Winkler IG, Eri R, Subramaniam N, Jinnah HA, McWhinney BC, Levesque JP, McGuckin MA, Duley JA, Florin TH.
    Gut; 2013 Apr 09; 62(4):594-605. PubMed ID: 22773547
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.